文献速递肝病消化道肿瘤与早癌

肝细胞癌患者序贯系统治疗的可行性与疗效分析

Sequential systemic treatment in patients with hepatocellular carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2020-05-20

这项多中心研究纳入2014至2019年间两家转诊中心接受新型系统治疗的85例肝细胞癌患者,其中89.4%接受至少一线以上治疗。结果显示序贯治疗组中位总生存期35个月,显著优于单线治疗的9个月(P<0.001),但48.6%患者肝功能恶化。

要点

  • 序贯系统治疗在部分肝细胞癌患者中可行且有效
  • 序贯治疗中位总生存期35个月,单线治疗仅9个月(P<0.001)
  • 48.6%患者序贯治疗期间肝功能恶化(Child-Pugh至少增加1分)

核心结论

  • 在临床实践中,对经过选择的肝细胞癌患者,序贯系统治疗是可行且有效的。
  • 研究强调保持良好肝功能对于成功实施序贯系统治疗至关重要。

研究设计与样本

  • 多中心研究,纳入德国汉诺威医学院和奥地利维也纳医科大学两家转诊中心2014至2019年间接受新型系统治疗的肝细胞癌患者。
  • 共纳入85例患者,其中76例(89.4%)接受超过一线、最多五线的系统治疗。

主要发现

  • 最常见的治疗顺序为索拉非尼(n=72;84.7%)后接瑞戈非尼(n=37;48.7%),11例(12.9%)初始接受仑伐替尼治疗。
  • 其他二线治疗包括帕博利珠单抗、纳武利尤单抗、卡博替尼和雷莫西尤单抗。
  • 序贯系统治疗期间48.6%的患者肝功能恶化(定义为Child-Pugh评分至少增加1分)。
  • 从首次系统治疗开始,序贯治疗患者的中位总生存期为35个月,单线治疗患者为9个月(P<0.001)。
  • 既往接受手术/局部治疗的患者中位总生存期长于初始即系统治疗的患者(66 vs 25个月;P=0.020)。

临床怎么用

  • 对肝功能储备良好的肝细胞癌患者,可考虑序贯多线系统治疗以延长生存。
  • 治疗过程中需密切监测肝功能(如Child-Pugh评分),及时调整治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most lethal cancers. After many years of stagnation, there are now several systemic treatments available for patients with HCC. AIM: To analyse the feasibility and efficacy of sequential systemic treatments in patients with HCC in clinical practice. METHODS: In this multicentre study, patients who were treated with novel systemic therapies for HCC between 2014 and 2019 at two referral centres, Hannover Medical School, Germany, and Medical University of Vienna, Austria, were included. RESULTS: Overall, 85 patients were included of which 76 patients (89.4%) received more than one and a maximum of five systemic treatment lines. The most common therapy sequence was sorafenib (n = 72; 84.7%) followed by regorafenib (n = 37; 48.7%), whereas 11 patients were initially treated with lenvatinib (12.9%). Other second-line treatments included pembrolizumab, nivolumab, cabozantinib and ramucirumab. Hepatic function deteriorated during sequential systemic treatment in 48.6% of the patients as defined by an increase in at least one Child-Pugh point. Median overall survival (mOS) from the start of first systemic treatment was 35 months for patients with sequential systemic treatment compared to 9 months for patients with one systemic treatment line (P < 0.001). Patients previously treated with surgical/locoregional therapies had a longer mOS compared to patients with initial systemic treatment (66 vs 25 months; P = 0.020). CONCLUSIONS: Sequential systemic treatment is feasible and effective in selected patients with HCC in clinical practice. Our study underlines the critical importance of well-preserved liver function for successful administration of sequential systemic therapy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kirstein MM, Scheiner B, Marwede T, et al. Sequential systemic treatment in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2020. PMID: 32432799. doi:10.1111/apt.15789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。